Williams Jones Wealth Management LLC. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 1.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 983,021 shares of the company’s stock after acquiring an additional 10,113 shares during the period. Zoetis accounts for approximately 2.6% of Williams Jones Wealth Management LLC.’s portfolio, making the stock its 8th biggest holding. Williams Jones Wealth Management LLC.’s holdings in Zoetis were worth $185,388,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of Zoetis by 3.6% during the first quarter. BlackRock Inc. now owns 41,766,559 shares of the company’s stock valued at $7,876,755,000 after acquiring an additional 1,450,749 shares during the last quarter. State Street Corp lifted its position in Zoetis by 2.7% during the fourth quarter. State Street Corp now owns 19,994,627 shares of the company’s stock worth $4,879,289,000 after buying an additional 529,974 shares during the period. Alliancebernstein L.P. lifted its position in Zoetis by 2.6% during the fourth quarter. Alliancebernstein L.P. now owns 17,663,325 shares of the company’s stock worth $4,310,381,000 after buying an additional 441,440 shares during the period. Geode Capital Management LLC lifted its position in Zoetis by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 8,710,236 shares of the company’s stock worth $2,120,301,000 after buying an additional 159,268 shares during the period. Finally, Norges Bank purchased a new position in Zoetis during the fourth quarter worth about $1,067,881,000. Institutional investors and hedge funds own 91.05% of the company’s stock.
In other news, EVP Roxanne Lagano sold 2,167 shares of the stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $180.26, for a total value of $390,623.42. Following the completion of the sale, the executive vice president now owns 23,687 shares in the company, valued at $4,269,818.62. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Zoetis news, EVP Roxanne Lagano sold 2,167 shares of the firm’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $180.26, for a total transaction of $390,623.42. Following the completion of the sale, the executive vice president now owns 23,687 shares in the company, valued at approximately $4,269,818.62. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Kristin C. Peck sold 9,689 shares of the firm’s stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $180.00, for a total value of $1,744,020.00. Following the sale, the chief executive officer now owns 39,743 shares of the company’s stock, valued at approximately $7,153,740. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,501 shares of company stock worth $2,949,073. 0.12% of the stock is currently owned by corporate insiders.
Zoetis Price Performance
ZTS stock opened at $164.31 on Friday. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.46 and a current ratio of 2.18. Zoetis Inc. has a 1 year low of $154.18 and a 1 year high of $249.27. The firm has a market cap of $76.92 billion, a P/E ratio of 37.26, a price-to-earnings-growth ratio of 2.80 and a beta of 0.77. The stock has a 50-day simple moving average of $170.78 and a 200-day simple moving average of $175.76.
Zoetis (NYSE:ZTS – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The company had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same quarter last year, the business posted $1.19 EPS. Zoetis’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities analysts predict that Zoetis Inc. will post 5.01 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on ZTS shares. StockNews.com upgraded Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Friday. Stifel Nicolaus reduced their target price on Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, June 24th. Piper Sandler started coverage on Zoetis in a research report on Monday, July 11th. They set an “overweight” rating and a $205.00 target price on the stock. William Blair restated an “outperform” rating on shares of Zoetis in a report on Friday, August 5th. Finally, The Goldman Sachs Group cut their price objective on Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a report on Thursday, July 21st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $224.00.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.